KNEE SURGERIES AND ARTHROPLASTY PAIN MANAGEMENT THERAPEUTICS MARKET ANALYSIS

Knee Surgeries and Arthroplasty Pain Management Therapeutics Market, by Drug (Acetaminophen, COX-2 inhibitors, Opioids, Non-steroidal Anti-inflammatories, Ketamine, and Others ), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies ), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Published In : Apr 2022
Code : CMI4998
Pages :177
Formats :
Excel and PDF
Industry : Pharmaceutical

Market News

For instance, in December 2021, Heron Therapeutics, Inc., a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, announced that the U.S. Food and Drug Administration (FDA) had approved its supplemental New Drug Application (sNDA) for ZYNRELEF (bupivacaine and meloxicam) extended-release solution to significantly expand the indication. ZYNRELEF is now indicated in adults for soft tissue or periarticular instillation to produce postsurgical analgesia for up to 72 hours after foot and ankle, small-to-medium open abdominal, and lower extremity total joint arthroplasty surgical procedures.